Replies to post #42895 on OncoSec Medical Inc (ONCSQ)

[InTheTrenches]

Dr. Algazi comment (principal investigator of Phase 2b EP IL-12 + Keytruda):

When he was asked what he predicts the ORR would be on the total population, not just patients refractory to anti-PD1 inhibitors, his answer was simply... "75%". (from Twitter--POUNDtheROCK author)


That is, he predicts ORR of tavo + Keytruda will be significantly better than 1st line treatment (Opdivo) in unresectable melanoma.

[dr_lowenstein]

cross study comparisons are scientifically meaningless